Unity Biotechnology, Inc. (0YC0.L)
USD 0.95
(-7.34%)
USD 0.95
(-7.34%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -37.28 Million USD | 33.86% |
| 2022 | -38.73 Million USD | 2.05% |
| 2021 | -54.66 Million USD | 36.03% |
| 2020 | -89.1 Million USD | 2.6% |
| 2019 | -89.65 Million USD | -31.22% |
| 2018 | -74.21 Million USD | -58.86% |
| 2017 | -44.3 Million USD | -375.67% |
| 2016 | -28.06 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -7.87 Million USD | -35.42% |
| 2024 Q2 | -9.95 Million USD | 9.08% |
| 2024 Q3 | -6.6 Million USD | -23.86% |
| 2023 Q2 | -10.91 Million USD | -10.64% |
| 2023 Q4 | -7.64 Million USD | 48.79% |
| 2023 FY | - USD | 30.84% |
| 2023 Q1 | -9.86 Million USD | 25.16% |
| 2023 Q3 | -14.93 Million USD | -36.83% |
| 2022 Q4 | -13.17 Million USD | -7.08% |
| 2022 Q3 | -12.3 Million USD | -5.78% |
| 2022 FY | - USD | 2.05% |
| 2022 Q2 | -11.63 Million USD | 33.44% |
| 2022 Q1 | -17.48 Million USD | -77.16% |
| 2021 Q1 | -14.22 Million USD | 22.38% |
| 2021 FY | - USD | 36.03% |
| 2021 Q4 | -9.86 Million USD | 34.0% |
| 2021 Q3 | -14.95 Million USD | 8.27% |
| 2021 Q2 | -16.29 Million USD | -14.58% |
| 2020 Q1 | -22.37 Million USD | 3.29% |
| 2020 FY | - USD | 2.6% |
| 2020 Q4 | -18.32 Million USD | 32.0% |
| 2020 Q2 | -20.62 Million USD | 7.82% |
| 2020 Q3 | -26.94 Million USD | -30.65% |
| 2019 Q3 | -23.94 Million USD | -10.03% |
| 2019 Q1 | -21.59 Million USD | -16.64% |
| 2019 FY | - USD | -31.22% |
| 2019 Q4 | -23.13 Million USD | 3.37% |
| 2019 Q2 | -21.76 Million USD | -0.8% |
| 2018 Q2 | -16.76 Million USD | -1.69% |
| 2018 FY | - USD | -58.86% |
| 2018 Q1 | -16.48 Million USD | -33.8% |
| 2018 Q4 | -18.51 Million USD | -5.49% |
| 2018 Q3 | -17.54 Million USD | -4.68% |
| 2017 Q2 | -11.4 Million USD | -27.48% |
| 2017 FY | - USD | -375.67% |
| 2017 Q1 | -8.94 Million USD | 0.0% |
| 2017 Q4 | -12.31 Million USD | -5.87% |
| 2017 Q3 | -11.63 Million USD | -2.03% |
| 2016 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 100.345% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 89.208% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 85.984% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 68.31% |
| uniQure N.V. | -253.1 Million USD | 85.269% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 59.51% |
| bluebird bio, Inc. | -167.16 Million USD | 77.696% |
| Imunon, Inc. | -20.78 Million USD | -79.398% |
| Dynavax Technologies Corporation | 9.66 Million USD | 485.713% |
| Editas Medicine, Inc. | -163.11 Million USD | 77.143% |
| Illumina, Inc. | -608 Million USD | 93.868% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 91.697% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 101.145% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 103.203% |
| Myriad Genetics, Inc. | -67.8 Million USD | 45.01% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 108.96% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 91.511% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 137.942% |
| Verastem, Inc. | -83.16 Million USD | 55.17% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 99.669% |
| Waters Corporation | 1.02 Billion USD | 103.647% |
| Biogen Inc. | 2.37 Billion USD | 101.568% |
| Nektar Therapeutics | -243.1 Million USD | 84.664% |
| Perrigo Company plc | 646.2 Million USD | 105.77% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 16.099% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 64.079% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 112.016% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 57.355% |
| Evolus, Inc. | -41.81 Million USD | 10.828% |
| Adicet Bio, Inc. | -136.53 Million USD | 72.693% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | 57.626% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 100.801% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 75.163% |
| FibroGen, Inc. | -261.4 Million USD | 85.737% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 102.223% |
| OPKO Health, Inc. | -65.51 Million USD | 43.093% |
| Homology Medicines, Inc. | -47.75 Million USD | 21.93% |
| Geron Corporation | -174.78 Million USD | 78.669% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 83.656% |
| Exelixis, Inc. | 196.6 Million USD | 118.964% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 63.023% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 33.132% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 92.636% |
| Zoetis Inc. | 3.68 Billion USD | 101.012% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 83.429% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 26.277% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 100.81% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -3.329% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 83.791% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 134.418% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 108.249% |
| Blueprint Medicines Corporation | -474.61 Million USD | 92.145% |
| Insmed Incorporated | -654.73 Million USD | 94.306% |
| TG Therapeutics, Inc. | 26.1 Million USD | 242.847% |
| Incyte Corporation | 919.42 Million USD | 104.055% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 92.622% |